New hope for Hard-to-Treat lymphoma: experimental drug DZD8586 enters phase 2 trial
NCT ID NCT06539195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an experimental drug called DZD8586 in 59 adults with diffuse large B-cell lymphoma that has come back or not responded to previous treatment. The study aims to see if the drug can shrink tumors and to understand its side effects and how the body processes it. Participants take one of three daily doses of DZD8586.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DZD8586
What this could lead to
If successful, this could provide a new oral treatment option for patients with DLBCL that has returned or not responded to prior therapy.
What could go wrong
This is a small, early-phase trial with no control group, so results may not confirm effectiveness. Side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
Research Site
Hefei, Anhui, 230031, China
-
Research Site
Beijing, Beijing Municipality, 100083, China
-
Research Site
Guangzhou, Guangdong, 510060, China
-
Research Site
Nanning, Guangxi, 530016, China
-
Research Site
Zhengzhou, Henan, 450003, China
-
Research Site
Wuhan, Hubei, 430023, China
-
Research Site
Changsha, Hunan, 410031, China
-
Research Site
Jinan, Shandong, 250117, China
-
Research Site
Linyi, Shandong, 276002, China
-
Research Site
Xi’an, Shanxi, 710061, China
-
Research Site
Chengdu, Sichuan, 610041, China
-
Research Site
Tianjin, Tianjin Municipality, 300181, China
-
Research Site
Hangzhou, Zhejiang, 310009, China